Cancer, Diet, and Funding: Food or Pharmaceuticals?

The chemoprevention field could be characterized as being in a double-blind double bind. One side of the field emphasizes taking a "whole food" approach to using food to prevent cancer. That approach entails having scientists closely monitor everything a necessarily small group of subjects eats over a necessarily short period of time. Such studies pick apart the complexities of diet and its possible roles in keeping cancer at bay. But the small numbers and short time frame put any conclusions o

Written byPaul Smaglik
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The chemoprevention field could be characterized as being in a double-blind double bind. One side of the field emphasizes taking a "whole food" approach to using food to prevent cancer. That approach entails having scientists closely monitor everything a necessarily small group of subjects eats over a necessarily short period of time. Such studies pick apart the complexities of diet and its possible roles in keeping cancer at bay. But the small numbers and short time frame put any conclusions on statistically shaky ground.

The other side analyzes the effect of one thing at a time--usually a supplement or combination of supplements. Such approaches ignore the complexity of dietary interactions and consequently yield unexpected and perhaps incomplete results. One large trial that tested beta carotene as a potential chemopreventive found that it actually increased cancer rates in smokers; a then-unknown dietary mechanism actually changed the supplement's touted antioxidant activity into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies